- Home
- EOSE vs RIGL Comparison
EOSE vs RIGL Comparison
Compare EOSE & RIGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EOSE
- RIGL
- Stock Information
- Founded
- EOSE 2008
- RIGL 1996
- Country
- EOSE United States
- RIGL United States
- Employees
- EOSE N/A
- RIGL N/A
- Industry
- EOSE Industrial Machinery/Components
- RIGL Biotechnology: Pharmaceutical Preparations
- Sector
- EOSE Miscellaneous
- RIGL Health Care
- Exchange
- EOSE Nasdaq
- RIGL Nasdaq
- Market Cap
- EOSE 542.2M
- RIGL 486.4M
- IPO Year
- EOSE N/A
- RIGL 2000
- Fundamental
- Price
- EOSE $4.48
- RIGL $20.09
- Analyst Decision
- EOSE Buy
- RIGL Buy
- Analyst Count
- EOSE 6
- RIGL 5
- Target Price
- EOSE $5.58
- RIGL $34.80
- AVG Volume (30 Days)
- EOSE 6.7M
- RIGL 226.6K
- Earning Date
- EOSE 03-04-2025
- RIGL 03-04-2025
- Dividend Yield
- EOSE N/A
- RIGL N/A
- EPS Growth
- EOSE N/A
- RIGL N/A
- EPS
- EOSE N/A
- RIGL 0.22
- Revenue
- EOSE $14,963,000.00
- RIGL $157,374,000.00
- Revenue This Year
- EOSE N/A
- RIGL $51.34
- Revenue Next Year
- EOSE $1,044.55
- RIGL $15.75
- P/E Ratio
- EOSE N/A
- RIGL $90.73
- Revenue Growth
- EOSE 20.34
- RIGL 21.65
- 52 Week Low
- EOSE $0.61
- RIGL $7.48
- 52 Week High
- EOSE $6.64
- RIGL $29.82
- Technical
- Relative Strength Index (RSI)
- EOSE 38.63
- RIGL 45.75
- Support Level
- EOSE $4.38
- RIGL $20.00
- Resistance Level
- EOSE $5.11
- RIGL $21.93
- Average True Range (ATR)
- EOSE 0.46
- RIGL 1.30
- MACD
- EOSE -0.14
- RIGL -0.27
- Stochastic Oscillator
- EOSE 5.76
- RIGL 2.01
About EOSE Eos Energy Enterprises Inc.
Eos Energy Enterprises Inc designs develop, manufactures, and markets zinc-based energy storage solutions for utility-scale, microgrid, and commercial & industrial (C&I) applications. The solutions are used in the utility sector, the renewable energy sector, and the industrial sector. It's flagship product Eos Znyth is a stationary battery energy storage system.
About RIGL Rigel Pharmaceuticals Inc.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's lead drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.